Details

Autor(en) / Beteiligte

• Qin, Jinling
• Li, Hongliang
• Wang, Xuan
• Zhang, Yixin
• Duan, Yongtao
• Yao, Yongfang
• Yang, Hua
• Sun, Moran

Titel

Discovery of a novel piperlongumine analogue as a microtubule polymerization inhibitor with potent anti-angiogenic and anti-metastatic efficacy

Ist Teil von

• European journal of medicinal chemistry, 2022-12, Vol.243, p.114738, Article 114738

Ort / Verlag

France: Elsevier Masson SAS

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• In an effort to discover anticancer agents with simultaneous effects on tubulin and angiogenesis, we designed and synthesized two series of piperlongumie (PL) derivatives by replacing of phenyl group with a variety of benzoheterocycle (series II) or cyclizing the C7–C8 olefin into an aromatic heterocycle (series I). Most of the new compounds showed better antiproliferative activities against six cancer cell lines than the parent drug PL. Compound II-14b had the best cytotoxic profile of these two series in cancer cells, whilst being relatively low cytotoxicity against normal human cells and high potency against drug-resistant cells. It disrupted cellular microtubule networks and inhibited tubulin assembly with an IC50 value of 5.8 μM. Further studies elucidated that II-14b showed antitumor activities through multiple mechanisms, including the pruduction of abundant ROS, the dissipation of mitochondrial membrane potential, the accumulation of DNA double-strand breaks, and the induction of cell cycle in G2/M phase. More importantly, we have observed that it possesses potential anti-angiogenesis capabilities, including suppression of HUVECs cell migration, invasion, and endothelial tube formation in vitro and in vivo. In vivo assessment indicated that II-14b inhibits the growth and metastasis of MGC-803 xenograft tumour in zebrafish. These findings show that II-14b is a high-efficacy and non-toxic antitumor agent. [Display omitted] •A total of fifty novel piperlongumine analogues were prepared as microtubule polymerization inhibitors.•II-14b exhibited higher selectivity than normal human cells, with an IC50 value of 0.458 ± 0.01 μM against MGC-803 cell line.•II-14b effectively attenuated the migration and invasion of MGC-803 cells by blocking the FAK, MMP9 and ERK/EMT pathway.•II-14b exhibited potent anti-angiogenesis effect through theVEGFR2/PI3K/AKT/MAPK pathway.